# Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

Source: https://onco.cc/trials/nct07471776/  
OnCo record `nct07471776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TROP2 PET in Breast cancer, run by Fudan University, now recruiting.

## Summary

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer is a phase 2 interventional study registered as NCT07471776 by Fudan University, with 45 participants planned, started 2026-03-11 and due to reach its primary completion in 2028-03-11. Interventions recorded: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan, 68Ga-TROP2 PET/CT Imaging, 18F-FDG PET Imaging. Conditions recorded: Metastatic Breast Cancer ( HER2 Negative).

Linked to the technology TROP2 PET because the registry names it ("trop2 pet") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07471776
- Phase: 2
- Setting: Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
- Sponsor: Fudan University
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07471776: https://clinicaltrials.gov/study/NCT07471776

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [TROP2 PET](https://onco.cc/technologies/trop2-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct07471776.json